

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q96012

Kiyotaka KUZUSHIMA

Appln. No.: National Stage of PCT/JP2005/00587

Confirmation No.: Not yet assigned Group Art Unit: Not yet assigned

Filed: July 20, 2006 Examiner: Not yet assigned

For: EPITOPE/PEPTIDE RECOGNIZED BY HLA-A2402-RESTRICTED EP/CAM-

SPECIFIC CTL AND USE OF THE SAME

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

A copy of an International Search Report in a counterpart application is submitted herewith. The USPTO should receive copies of the references cited in the International Search Report from the International Bureau. Applicants will furnish any missing references upon request.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office

01966, 10 50

INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: National Stage of PCT/JP2005/000587

Attorney Docket No. Q96012

Action after filing a request for continued examination (RCE) under §1.114, and therefore, no

Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3)

for foreign language documents, Applicant encloses herewith a copy of a Communication

from a foreign patent office in a counterpart application citing such documents (International

Search Report for PCT/JP2005/000587 dated May 10, 2005), together with an English-

language version (if not already included) of at least that portion of the Communication

indicating the degree of relevance found by the foreign patent office.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does

not waive any right to take any action that would be appropriate to antedate or otherwise

remove any listed document as a competent reference against the claims of the present

application.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account.

Respectfully submitted,

Registration No. 30,764

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: July 20, 2006

2

Substitute for Form 1449 A & B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 1

Complete if Known				
	National Stage of			
Application Number	PCT/JP2005/000587			
Confirmation Number	Notive assigned 2 0 00			
Filing Date	July 20, 2006 9 9 9 7 2			
First Named Inventor	Kiyotaka KUZUSHIMA			
Art Unit	Not yet assigned			
Examiner Name	Not yet assigned			
Attorney Docket Number	Q96012			

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document	Number	Publication Date MM-DD-YYYY		
		Number	Kind Code ² (if known)		Name of Patentee or Applicant of Cited Documen	
		US				
	-	US				
		US				
		US				
		US				
		US				
		US				
	· -	US				
		US				

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date	Name of Patentee or	
		Country Code ³	Number⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶
		wo	97/15597	A1	05-01-1997	CENTOCOR B V	
		JР	11-318455	Α	11-24-1999	KYOGO ITO	
		wo	03/012086	Al	02-13-2003	SIGUMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.	
		JР	2002-510496	A	04-09-2002	GLAXO GROUP LTD.	
		JP	2003-533175	А	11-11-2003	LUDWIG INSTITUTE FOR CANCER RESEARCH	
		JP	2003-510334	A	03-18-2003	CORIXA CORP.	
		JP	2000-116383	A	04-25-2000	KYOGO ITO	
		JP	2001-245675	A	09-11-2001	KYOGO ITO	
		 					<u> </u>

		NON PATENT LITERATURE DOCUMENTS			
Examiner Cite Initials* No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.			
		K.C. PARKER et al., "Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptie side-chains", J. Immnol., Vol. 152, pages 163-175, (1974)			
1 70					
			<u> </u>		

Examiner Signature	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.